Data gathered: October 8
Alternative Data for ProPhase Labs
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 47 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,476 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| X Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About ProPhase Labs
ProPhase Labs, Inc. is engaged in the research, development, manufacture, distribution, marketing, and sale of consumer health products and over-the-counter (OTC) dietary supplements in the United States. The company is headquartered in Garden City, New York.
| Price | $0.61 |
| Target Price | Sign up |
| Volume | 3,150,000 |
| Market Cap | $25M |
| Year Range | $0.24 - $0.61 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
ProPhase Labs continues exploration of crypto treasury strategySeptember 22 - Thefly.com |
 |
ProPhase Labs (NASDAQ:PRPH) Upgraded by Wall Street Zen to Hold RatingSeptember 12 - ETF Daily News |
|
ProPhase Labs stockholders approval all proposals at Special MeetingSeptember 12 - Thefly.com |
ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In FavorSeptember 12 - GlobeNewswire |
|
|
ProPhase Labs (NASDAQ:PRPH) Stock Price Passes Above 200 Day Moving Average – Should You Sell?September 4 - ETF Daily News |
 |
Biotech firm files Chapter 11 bankruptcy for 3 labs, explores crypto planSeptember 23 - TheStreet |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 1.2M | 510,000 | 730,000 | -4.5M | -3.9M | -0.110 |
| Q1 '25 | 1.4M | 910,000 | 530,000 | 4M | -2.5M | -0.133 |
| Q4 '24 | -2.5M | -3.4M | 920,000 | -34M | 0 | -1.590 |
| Q3 '24 | 3.1M | 3.3M | -170,000 | -6.6M | -5.4M | -0.350 |
| Q2 '24 | 2.5M | 3M | -480,000 | -6.2M | -6.1M | -0.330 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Read more about ProPhase Labs (PRPH) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, x mentions, news mentions & customer reviews.
What is the Market Cap of ProPhase Labs?
The Market Cap of ProPhase Labs is $25M.
What is the current stock price of ProPhase Labs?
Currently, the price of one share of ProPhase Labs stock is $0.61.
How can I analyze the PRPH stock price chart for investment decisions?
The PRPH stock price chart above provides a comprehensive visual representation of ProPhase Labs' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ProPhase Labs shares. Our platform offers an up-to-date PRPH stock price chart, along with technical data analysis and alternative data insights.
Does PRPH offer dividends to its shareholders?
As of our latest update, ProPhase Labs (PRPH) does not offer dividends to its shareholders. Investors interested in ProPhase Labs should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ProPhase Labs?
Some of the similar stocks of ProPhase Labs are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
